Through this deal, expected to close by year end, Mylan intends to strengthen its presence in the high potential generic injectables market. Mylan also intends to utilize the funds for general corporate purposes and share repurchases. Apart from the pricing of senior notes, Mylan was also in the news when it launched its generic version of Novartis ' ( NVS ) attention deficit hyperactivity disorder ( ADHD ) treatment, Focalin XR (dexmethylphenidate hydrochloride extended-release) capsules (30 mg) in the U.S. With Mylan being the first to file, the company will enjoy 180 days of marketing exclusivity. As per IMS data, as of Sep 30, 2013, Focalin annual sales were approximately $67.34 million in the U.S. Mylan, one of the largest players in the global generics market, has a presence in approximately 140 countries. As of Nov 18, 2013, the company had 179 abbreviated new drug applications pending approval by the U.S. Food and Drug Administration (:FDA), representing $90.5 billion in annual sales.